Ramón B. Colón Rivera

A Comparison of different

treatments for HCV

Background

Hepatitis C (HCV) is an inflammatory disease that

affects the liver.

Infection with hepatitis C virus (HCV) is one of the

leading causes of liver failure worldwide, and

resulted in 195 000 deaths in 2010 (Jacobson et

al. 2014).

Background

People at risk are those who:

Unprotected sex with someone who has the

disease

Received an organ transplant from a donor with the

virus

Blood related infection

Background

Approximately 75%–85% of people who become

infected with Hepatitis C virus develop chronic

infection.

Three percent of the world's population is

chronically infected.

Japan has one of the highest rates of hepatitis C

virus (HCV) infection worldwide, with around 2

million people estimated to be infected (Hayashi

et al. 2014).

Sofosbuvir (GS-7977) plus

peginterferon/ribavirin

Patients :

18–65 years old

44 weeks

Sofosbuvir is a pyrimidine nucleotide analog

inhibitor of the hepatitis C virus NS5B polymerase

(Rodríguez et al. 2013).

During day 28 the dosing period, sofosbuvir was

generally safe and well-tolerated (Rodríguez et al.

2013).

Sofosbuvir (GS-7977) plus

peginterferon/ribavirin

(Rodríguez et al. 2013)

Sofosbuvir (GS-7977)

(Liu et al. 2014)

Sofosbuvir (GS-7977)

In conclusion, sofosbuvir-based treatment is

effective and safe in treating chronic HCV

infection, although the SVR*12 of its combination

with RBV, especially in treatment-experienced

patients, requires improvement (Liu et al. 2014).

*SVR= Sustained Virologic Response

IFN-β/RBV and PEG-IFN/RBV

Patients:

65 or older

24–48 weeks

IFN-β/RBV therapy is associated with a lower

incidence of the onset of depression symptoms or

insomnia (Nomura et al. 2014).

The SVR rates of both treatments were similar.

IFN-β/RBV and PEG-IFN/RBV

(Nomura et al. 2014)

Simeprevir plus peginterferon alpha-

2a/ribavirin

Patients:

20–70 years

12 or 36 weeks

Simeprevir plus peginterferon alpha-

2a/ribavirin

(Hayashi et al. 2014)

Simeprevir plus peginterferon alpha-

2a/ribavirin

Patients

18 years and older (HCV genotype 1)

48 weeks

Simeprevir (SVR) plus peginterferonalpha-2a/ribavirin (PegIFNα-2a/RBV)

(Jacobson et al. 2014)

Conclusion

Sofosbuvir with ribavirin and pegylated interferon-

α is the best treatment to battle the Hepatitis C

because is the most efficient, safest and have the

best SVR12 percent. Have a SVR 12 of 89% and

a SVR 24 of 91%.

(Liu et al. 2014)

Cited References Hayashi N, Izumi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H,

Kato M, Ki R, Komada Y, Seto C, Goto S.2014.Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial.J of Hepathology [Internet].[cited 2014 October 9];61(2):219-227.Available from: http://www.sciencedirect.com.uprcdb.cayey.upr.edu:2048/science/article/pii/S0168827814002219?np=y

Jacobson I, Dore G, Foster G, Fried M, Radu M, Rafalsky V, Moroz L, Craxi A, Peeters M, Lenz O et al.2014. Simeprevir with pegylatedinterferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.The Lancet [Internet].[cited 2014 october 31];384(9941):403-413.Available from: http://www.sciencedirect.com.uprcdb.cayey.upr.edu:2048/science/article/pii/S0140673614604943?np=y

Cited References Liu X, Wang Y, Zhang G, Li N, Zhu G, Chang H, Han Q, Lv Y, Liu

Z.2014. Efficacy and safety of sofosbuvir-based therapy for the

treatment of chronic hepatitis C in treatment-naïve and treatment-

experienced patients.Int J of Antimicrobial Agents[Internet].[cited

2014 October 2];44(2):145-151.Available from:

http://www.sciencedirect.com.uprcdb.cayey.upr.edu:2048/science/

article/pii/S0924857914001630?np=y

Nomura H, Miyagi Y, Tanimoto H et al.2013.Interferon-beta plus ribavirin

therapy can be safely and effectively administered to elderly

patients with chronic hepatitis C.Journal of Infection and

Chemotherapy[Internet]; [cited 2014 September 25]; 20 (8): 489 -

492. Available from:

http://www.sciencedirect.com.uprcdb.cayey.upr.edu:2048/science/

article/pii/S1341321X14001755?np=y

Cited References

Rodríguez M, Lawitz E, Kowdley K, Nelson D,

DeJesus E, McHutchison J, Cornpropst M,

Mader M, Albanis E, Jiang D et al.2013.

Sofosbuvir (GS-7977) plus

peginterferon/ribavirin in treatment-naïve

patients with HCV genotype 1: A randomized,

28-day, dose- ranging trial.J of

Hepatology[Internet];[cited 2014 October

31];58(4):663-668.Available from:

http://www.sciencedirect.com.uprcdb.cayey.u

pr.edu:

2048/science/article/pii/S0168827812008872

?np=y